Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial

Vaccine

Volumn 24, Issue 33-34, 2006, Pages 5950-5959

  Gorse, Geoffrey J ^a   Keitel, Wendy ^b   Keyserling, Harry ^c   Taylor, David N ^d   Lock, Michael ^e   Alves, Katia ^e   Kenner, Julie ^e   Deans, Lynne ^e   Gurwith, Marc ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^e VaxGen Inc   (United States)

Author keywords

Anthrax vaccines; Clinical trial phase I; Immunogenicity; Recombinant vaccines; Safety

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G; RECOMBINANT PROTECTIVE ANTIGEN ANTHRAX VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTHRAX; ANTIBODY RESPONSE; APPETITE DISORDER; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BACILLUS ANTHRACIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; GEOMETRY; HEADACHE; HEAT SENSATION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INJECTION SITE REACTION; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INDURATION; SWELLING; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; MALE; NEUTRALIZATION TESTS; VACCINES, SYNTHETIC;

EID: 33746058634     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.044     Document Type: Article

References (44)

1. Cole L.A. The specter of biological weapons. Sci Am 275 6 (1996) 60-65
2. Moayeri M., Haines D., Young H.A., and Leppla S.H. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 112 5 (2003) 670-682
3. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7 6 (2001) 933-944
4. During R.L., Li W., Hao B., Koenig J.M., Stephens D.S., Quinn C.P., et al. Anthrax lethal toxin paralyzes neutrophil actin-based motility. J Infect Dis 192 5 (2005) 837-845
5. Agrawal A., and Pulendran B. Anthrax lethal toxin: a weapon of multisystem destruction. Cell Mol Life Sci 61 22 (2004) 2859-2865
6. Joellenbeck L., Zwanziger L., Durch J., and Strom B. The anthrax vaccine is it safe? Does it work?. 2nd ed. (2002), National Academy Press, Washington, DC
7. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 9 8 (1991) 533-539
8. Brachman P., Gold H., Plotkin S., Fekety R., Werrin M., and Ingraham N. Field evaluation of a human anthrax vaccine. Am J Public Health 52 (1962) 632-645
9. DHHS-FDA. 51058. Federal Register, Vol. 50, No 240. Friday, December 13, 1985. Part II. In, FDA, 1985.
10. Sever J.L., Brenner Al, Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS). Pharmacoepidemiol Drug Saf 13 12 (2004) 825-840
11. Sato P., Ryan M., Gray G., et al. Surveillance for adverse events associated with anthrax vaccination-US Department of Defense, 1998-2000. MMWR Morb Mortal Wkly Rep 49 16 (2000) 341-345
12. Shah C., Lemke S., Singh V., and Gentile T. Case reports of aplastic anemia after vaccine administration. Am J Hematol 77 2 (2004) 204
13. Geier M.R., and Geier D.A. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the vaccine adverse events reporting system (VAERS) database. Hepatogastroenterology 51 57 (2004) 762-767
14. Mahan C.M., Kang H.K., Dalager N.A., and Heller J.M. Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and Their Families. Ann Epidemiol 14 2 (2004) 81-88
15. Joellenbeck L., Zwanziger L., Durch J., and Strom B. Chapter 7: anthrax vaccine manufacture. The anthrax vaccine is it safe? Does it work? (2002), National Academy Press, Washington, DC p. 180-197
16. Leppla S.H., Robbins J.B., Schneerson R., and Shiloach J. Development of an improved vaccine for anthrax. J Clin Invest 10 2 (2002) 141-144
17. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 9-10 (2002) 1412-1420
18. Pittman P.R. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 20 Suppl. 3 (2002) S48-S50
19. Whiting G.C., Rijpkema S., Adams T., and Corbel M.J. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 22 31-32 (2004) 4245-4251
20. Joellenbeck L., Zwanziger L., Durch J., and Strom B. Chapter 8: future needs. The anthrax vaccine is it safe? Does it work? (2002), National Academy Press, Washington, DC p. 198-210
21. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 8 10 (2002) 1103-1110
22. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190 7 (2004) 1228-1236
23. Semenova V.A., Steward-Clark E., Stamey K.L., Taylor Jr. T.H., Schmidt D.S., Martin S.K., et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 11 5 (2004) 919-923
24. Beyer W.H. CRC standard probability and statistics, tables and formulae (1990), CRC Press, Boca Raton, FL p. 1-2
25. Joellenbeck L., Zwanziger L., Durch J., and Strom B. Chapter 6: safety epidemiologic studies. The anthrax vaccine is it safe? Does it work? (2002), National Academy Press, Washington, DC p. 118-179
26. Pittman P.R., Gibbs P.H., Cannon T.L., and Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 20 5-6 (2002) 972-978
27. Ivins B.E., and Welkos S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4 1 (1988) 12-19
28. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 7 (2001) 4509-4515
29. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
30. Barnard J.P., and Friedlander A.M. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun 67 2 (1999) 562-567
31. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 5 (2001) 2888-2893
32. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 68 8 (2000) 4549-4558
33. Little S.F., Webster W.M., Norris S.L., and Andrews G.P. Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice. Biologicals 32 2 (2004) 62-69
34. NIAID. use of recombinant protective antigen (rPA) vaccine for post-exposure prophylaxis (PEP) emergency use (version PEP-1.0-06-10-03). In, http://www2.niaid.nih.gov/Biodefense/Research/products.htm#c, 2003a.
35. Parreiras P, Sirota L, Wagner L, Menzies S, Arciniega J. Agreement between estimates of antibodies induced by anthrax vaccines containing protective antigen, using ELISA and Toxin neutralization. In: ASM Biodefense Research Meeting, poster #201; 15-18 February 2006; Washigton, DC; 2006. p. 67.
36. NIAID. Anthrax vaccine development-animal study development plans to support general use prophylaxis (GUP) indication and post-exposure prophylaxis (PEP) indication under emergency-use conditions. In, http://www2.niaid.nih.gov/Biodefense/Research/products.htm#a, 2003b.
37. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 2 (1986) 509-512
38. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 2 (1986) 356-363
39. Pitt M, Ivins B, Estep J, et al. Comparison of the efficacy of purufied protective antigen and MDPH to protect non-human primates from inhalation anthrax. Salisbury Med Bull 1996;Suppl. 87:130.
40. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 11-12 (1998) 1141-1148
41. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282 22 (1999) 2104-2106
42. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L., Rossi C.A., Gibbs P.H., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19 23-24 (2001) 3241-3247
43. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 3-4 (2004) 422-430
44. Keyserling H., Gorse G., Keitel W., Taylor D., Longhi M., Hirsh A., et al. Ascending dose safety and immunogenicity study of a recombinant protective antigen (PA) vaccine (rPA102). International Conference on Emerging Infectious Diseases. Atlanta, Georgia, USA, 2004 (2004) 197